Consolidation of Pharmaceutical Development and Production Capabilities and Launch of Contract Projects
First written in FY2021. 8 of 14 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2023: 1 of 7 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Sales of in-house manufactured active pharmaceutical ingredients also performed well, driven by strong sales of the new product launched in the second quarter as well as solid sales of existing products.」
The new in-house manufactured active pharmaceutical ingredient launched in the second quarter progressed to the stage of contributing to sales. - FY2026-H1AdvancedAnnual report
「For in-house manufactured active pharmaceutical ingredients, the launch of new products contributed to higher sales in the current fiscal year, in addition to stable demand for existing products.」
The launch of new in-house manufactured active pharmaceutical ingredients reached the stage of contributing to higher sales. - FY2025-H1Expenses related to the relocation of the development centerAnnual report
「In addition, development expenses increased due to costs related to the relocation of the development center and higher depreciation expenses.」
The company states that costs related to the relocation of the development center and higher depreciation expenses were incurred in connection with its pharmaceutical development operations. It does not explicitly state that the relocation was completed. - FY2024-Q3AdvancedAnnual report
「Sales of in-house manufactured products, including active pharmaceutical ingredients, significantly exceeded the year-earlier level, supported by continued strong sales of existing core products and contributions from new products launched in the third quarter.」
A new product was launched in the pharmaceuticals business in the third quarter, contributing to higher sales of in-house manufactured products. - FY2024-Q2AdvancedAnnual report
「Sales of in-house manufactured products, including active pharmaceutical ingredients, significantly exceeded the year-earlier level, supported by strong sales of existing core products and the launch of several new products in the second quarter.」
Several new products were launched in the pharmaceuticals business in the second quarter, contributing to higher sales of in-house manufactured products. - FY2024-Q1RestatedAnnual report
「In addition, selling, general and administrative expenses and development expenses increased as a result of proactive investment in sales and development.」
The company explains that it continues to invest proactively in sales and development in the pharmaceuticals business. - FY2023RestatedAnnual report
「The acquisition of new processing and contract synthesis projects also progressed smoothly.」
The company continues to explain that the acquisition of new pharmaceutical processing and contract synthesis projects is progressing smoothly. - FY2022AdvancedAnnual report
「The acquisition of new processing and contract synthesis projects also progressed well.」
The acquisition of new pharmaceutical processing and contract synthesis projects progressed well, with progress in launching projects following the consolidation of development and production operations. - FY2022-Q3RestatedAnnual report
「Sales increased as sales of active pharmaceutical ingredients for antiepileptic drugs, a core product, remained strong, while the acquisition of new processing projects and small-scale synthesis projects also progressed favorably.」
The company continues to explain that the acquisition of new processing and small-batch synthesis projects is progressing well. - FY2022-Q2AdvancedAnnual report
「In addition to steady sales of active pharmaceutical ingredients for hyperkalemia treatments and antiepileptic drugs, the acquisition of new contract processing projects and small-batch synthesis projects is progressing ahead of expectations.」
The acquisition of new pharmaceutical processing and small-batch synthesis projects progressed ahead of expectations. - FY2022-Q1AdvancedAnnual report
「In addition, the acquisition of new contract processing projects is progressing smoothly.」
The acquisition of new contract processing projects in the pharmaceuticals business is progressing smoothly, indicating progress in launching contract manufacturing projects. - FY2021First statedAnnual report
「For in-house API synthesis and contract processing, we consolidated the production function at the head office plant and the development function at the Saitama Development Center, establishing an integrated development and production structure.」
The company has consolidated production at the head office plant and development at the Saitama Development Center, and is proceeding with the launch of projects involving API synthesis, purification, milling and foreign-matter removal.